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Invasive aspergillus infection of the larynx is extremely rare. This report describes the case of a 56-year-
old lady with Chronic Obstructive Pulmonary Disease receiving long-term inhaled corticosteroids who
presented with a four-week history of progressive hoarseness, dyspnoea and cough. Sputum cultures at
the time isolated Aspergillus fumigatus. She was commenced on a trial of Itraconazole for presumed
Allergic Bronchopulmonary Aspergillosis. Due to the duration and nature of her symptoms, vocal cord
biopsies were taken which revealed abundant colonies of the fungus A. fumigatus inﬁltrating skeletal
muscle. Inhaled corticosteroids were discontinued and the patient was switched to voriconazole. She
continues to make a protracted recovery and is being closely monitored.
 2011 Elsevier Ltd. All rights reserved.1. Case report
A 56-year-old lady presented with a four-week history of
hoarseness, progressive dyspnoea and cough. She is regularly
reviewed at chest clinic for management of Bronchiectasis and
Chronic Obstructive Pulmonary Disease. She is an ex-smoker, having
quit three years previously and had a forty pack year smoking history.
The patient had no history of immunosuppression, but had been
treated with inhaled corticosteroids for a number of years and had
received approximately ﬁve courses of oral steroids for exacerba-
tions of COPD over the preceding twelvemonths. At presentation her
medications included ﬂuticasone proprionate in a daily dose of 1mg.
Nystatin had been started in the community for presumed oral
candiadiasis related to her prolonged use of inhaled corticosteroids.
On examination, bibasal crepitations were heard. There was no
evidence of active lung disease on Chest X-ray, the heart was not
enlarged.
Recent sputum samples had cultured Aspergillus fumigatus. IgE
to A. fumigatus was elevated at 1.2 Ku/L (normal range 0e0.35),
suggesting the possibility of Allergic Bronchopulmonary Aspergil-
losis. Total IgE at the time was 31 Ku/L (normal range 0e81 Ku/L).
IgG antibodies to A. fumigatus were not detected. She was trialled
on Itraconazole 100 mg BD for presumed Allergic Bronchopulmo-
nary Aspergillosis.
Given the duration and nature of her symptoms, she was
referred for an ENT opinion. Fibreoptic laryngoscopy revealed
inﬂamed vocal cords with a white, slightly leukoplakic area to the
middle third bilaterally. There was no hearing impairment detected
on pure tone audiogram performed at this time.Naseer).
rved.Vocal cord biopsies were taken at microlaryngoscopy. Histology
from both the right and left vocal cords revealed inﬂammatory cells
and necrotic debris in which abundant colonies of aspergillus were
identiﬁed. There was evidence of chronic inﬂammatory change
within skeletal muscle and respiratory epithelium on the tissue
specimen taken from the Left vocal cord. In addition, some colonies
of aspergillus were noted within the skeletal muscle. In one of the
levels a detached fragment of stratiﬁed squamous epithelium,
devoid of underlying stroma with atypical features amounting to
mild dysplasia was visualised.
After discussion with the microbiology department she was
commencedonvoriconazole200mgoncedaily. Titresweremeasured
to ensure voriconazole levels were within the therapeutic range.
Both inhaled and oral corticosteroids were discontinued. She is
continuing to make a steady, albeit slow recovery. There was
marked improvement in the appearance of her larynx at repeat
laryngoscopy.
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Aspergillosis refers to the clinical spectrum of diseases ranging
from localised allergic responses to invasive infections carrying
a signiﬁcant mortality rate reported at between 25 and 90 percent.1
A. fumigatus is the underlying organism in the majority of cases.
It is one of the most ubiquitous of the airborne saprophytic fungi.
Animals and humans inhale numerous conidia of this fungus on
a daily basis,2 although infection normally only occurs in immu-
nocompromised individuals.
Invasive aspergillosis is themost aggressive form of aspergillosis
and varies in clinical course and severity. It is largely dependent
upon the affected organ and the host. It usually affects the lungs but
can also affect other organs including the heart, joints and sinuses.2
The usual pathogenesis involves dissemination from a primary
site of infection, most commonly the lungs or paranasal sinuses.1 In
this patient, A. fumigatus had been isolated on sputum culture on
several occasions, suggesting a concomitant pulmonary element.
The patient also had a long history of inhaled steroid administra-
tion, a risk factor for development of invasive aspergillosis. Other
predisposing factors include chemotherapy, neutropenia, stem cell
and organ transplantation and AIDS.2
Corticosteroids are known to augment fungal colonisation of
epithelial surfaces. Common side effects include corticosteroid
induced laryngitis and oropharyngeal candidiasis. The latter has
been reported in up to four percent of patients receiving ﬂuticasone
treatment, when given at a dose of 1.5e2 mg daily.3,4 Research has
shown that a substantial proportion of corticosteroid is deposited
in the upper airway, including the larynx, when inhaled via dry
powder devices. Fluticasone is the most potent steroid used in this
form.3 It has greater topical potency, a higher degree of retention in
tissue, and a longer half-life than the other inhaled corticosteroids.
Patients receiving daily doses exceeding 0.8 mg are at increased
susceptibility of developing both systemic and local effects of this
medication, including damage to epithelial cell architecture.4
Initially oedema and erythema can occur. Severe reactions are
associated with leukoplakia, granulation and laryngeal
candidiasis.5
A literature search over the past 35 years has revealed less than
14 cases of invasive laryngeal aspergillosis, of these, more than half
are associated with immunodeﬁciency states. In 1997, one case of
invasive laryngeal aspergillosis associated with high dose inhaled
corticosteroids was reported in Stafford, UK.6 In this case, the
patient had been administering ﬂuticasone at a daily dose of 2 mg;
double the dose received by the patient in this case. To date, no
further cases have been reported.
In summary, the scarcity of reported cases reﬂects the resilience
of the larynx and the resistance of the upper airways to colonisation
with aspergillus. Immunocompetent patients are rarely affected. In
this case it would appear that the development of the condition
was multifactorial. Initial pulmonary infection occurred with A.
fumigatus, being isolated on sputum sample prior to the develop-
ment any symptoms suggestive of vocal cord dysfunction. Thelaryngeal epithelial cells were at increased susceptibility of
opportunistic fungal infections due to long-term inhalation and
regular use of oral courses of corticosteroids.Patients with Chronic Obstructive Pulmonary Disease and
asthma are vulnerable to developing this genre of infection.
Pulmonary scarring resulting from recurrent infections increases
the risk of developing ABPA. Furthermore, the concurrent use of
inhaled corticosteroids, the mainstay and ﬁrst line treatment of
these conditions, renders the upper airways and larynx at increased
risk of aspergillus colonisation, especially when used at high
concentrations and with more potent formulations.
Presentationwith progressive hoarseness is a common ﬁnding.7
Patients with risk factors for invasive laryngeal aspergillosis,
including patients receiving inhaled corticosteroids, should be
referred for laryngoscopy if dysphonia, frequently associated with
corticosteroid induced laryngitis and oropharyngeal candidiasis,
does not improve with conventional therapy. At a time when the
prevalence of COPD and Asthma are increasing, physicians need to
be aware of this uncommon, but distressing and treatable side
effect of such medications.References
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